Acne Care Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
|
|
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. During clinical trials, 1401 subjects were exposed to EPIDUO gel. A total of 1036 subjects with acne vulgaris, 12 years and older, were treated once daily for 12 weeks to 12 months. Related adverse events reported within 12 weeks of treatment and in at least 1% of subjects treated with EPIDUO gel and those reported in subjects treated with the vehicle gel are presented in Table 1:
Table 1 : Drug Related Adverse Events Reported in Clinical
Trials by At Least 1% of Patients Treated For 12 Weeks
| System Organ Class/ Preferred Term | EPIDUO gel N = 564 |
Vehicle gel N = 489 |
| Subjects with AE (s) | 14% | 4% |
| Dry Skin | 7% | 2% |
| Contact dermatitis | 3% | < 1% |
| Application site burning | 2% | < 1% |
| Application site irritation | 1% | < 1% |
| Skin irritation | 1% | 0% |
Local tolerability evaluations, presented in Table 2, were conducted at each study visit in clinical trials by assessment of erythema, scaling, dryness, burning, and stinging.
Table 2 : Incidence of Local Cutaneous Irritation in Controlled
Clinical Trials (N = 553) Treatment Emergent Signs and Symptoms
| Maximum Severity During Treatment | End of Treatment Severity (12 Weeks) | |||||
| Mild | Moderate | Severe | Mild | Moderate | Severe | |
| Erythema | 27% | 13% | 1% | 8% | 2% | 1% |
| Scaling | 35% | 11% | 1% | 9% | 1% | < 1% |
| Dryness | 41% | 13% | 1% | 10% | 2% | < 1% |
| Stinging/burning | 41% | 15% | 3% | 7% | 2% | 1% |
Analysis over the 12-week period showed that local tolerability scores for erythema, scaling, dryness, and stinging/burning peaked at Week 1 of therapy and decreased thereafter.
The following adverse reactions have been identified during postapproval use of EPIDUO Gel: eyelid edema, sunburn, blister, pain of skin, pruritus, swelling face, conjunctivitis, skin discoloration, rash, eczema, throat tightness and allergic contact dermatitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. No formal drug-drug interaction studies were conducted with EPIDUO gel.
Last reviewed on RxList: 1/5/2012
This monograph has been modified to include the generic and brand name in many instances.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.